BR112015011756A2 - inibidores da glutamase e métodos de uso - Google Patents
inibidores da glutamase e métodos de usoInfo
- Publication number
- BR112015011756A2 BR112015011756A2 BR112015011756A BR112015011756A BR112015011756A2 BR 112015011756 A2 BR112015011756 A2 BR 112015011756A2 BR 112015011756 A BR112015011756 A BR 112015011756A BR 112015011756 A BR112015011756 A BR 112015011756A BR 112015011756 A2 BR112015011756 A2 BR 112015011756A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- glutamase
- inhibitors
- compounds
- inhibit glutaminase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
resumo inibidores da glutamase e métodos de uso compostos e composições compreendendo compostos que inibem a glutaminase são aqui descritos. são também aqui descritos métodos de uso de compostos que inibem a glutaminase no tratamento do câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261729321P | 2012-11-21 | 2012-11-21 | |
PCT/US2013/071212 WO2014081925A1 (en) | 2012-11-21 | 2013-11-21 | Glutamase inhibitors and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015011756A2 true BR112015011756A2 (pt) | 2017-07-11 |
Family
ID=49780330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015011756A BR112015011756A2 (pt) | 2012-11-21 | 2013-11-21 | inibidores da glutamase e métodos de uso |
Country Status (15)
Country | Link |
---|---|
US (3) | US10011574B2 (pt) |
EP (1) | EP2922832B1 (pt) |
JP (1) | JP6333280B2 (pt) |
KR (1) | KR20150085078A (pt) |
CN (1) | CN105263915B (pt) |
AU (2) | AU2013347933C1 (pt) |
BR (1) | BR112015011756A2 (pt) |
CA (1) | CA2892089A1 (pt) |
EA (1) | EA029531B1 (pt) |
ES (1) | ES2761951T3 (pt) |
HK (1) | HK1213889A1 (pt) |
IL (1) | IL238959A (pt) |
MX (1) | MX369691B (pt) |
SG (1) | SG11201504022RA (pt) |
WO (1) | WO2014081925A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6026424B2 (ja) | 2010-11-01 | 2016-11-16 | シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. | 治療薬送達のための生物浸食性ケイ素ベースのデバイス |
US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
EA029707B1 (ru) | 2012-11-16 | 2018-05-31 | Калитера Байосайенсиз, Инк. | Гетероциклические ингибиторы глютаминазы |
ES2761951T3 (es) * | 2012-11-21 | 2020-05-21 | Agios Pharmaceuticals Inc | Inhibidores de glutaminasa y métodos de uso |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
CA2934700A1 (en) | 2014-01-06 | 2015-07-09 | Rhizen Pharmaceuticals Sa | Glutaminase inhibitors |
AU2015231053B2 (en) | 2014-03-21 | 2019-04-11 | Les Laboratoires Servier | Compounds and their methods of use |
NZ725496A (en) | 2014-04-30 | 2019-11-29 | Pfizer | Cycloalkyl-linked diheterocycle derivatives |
GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
CA2952213A1 (en) * | 2014-06-13 | 2015-12-17 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
WO2016004404A2 (en) * | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Gls1 inhibitors for treating disease |
US10660861B2 (en) | 2014-07-09 | 2020-05-26 | The Johns Hopkins University | Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy |
WO2016014890A1 (en) * | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
WO2016022465A1 (en) * | 2014-08-04 | 2016-02-11 | Drexel University | Novel compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same |
JP6889101B2 (ja) | 2014-08-07 | 2021-06-18 | キャリセラ バイオサイエンシーズ, インコーポレイテッド | グルタミナーゼ阻害剤の結晶形態 |
MX2017012408A (es) * | 2015-03-30 | 2018-04-26 | Calithera Biosciences Inc | Metodos para administrar inhibidores de glutaminasa. |
JP6944377B2 (ja) | 2015-04-06 | 2021-10-06 | キャリセラ バイオサイエンシーズ, インコーポレイテッド | グルタミナーゼの阻害剤を用いる肺がんの処置 |
JP6895396B2 (ja) | 2015-06-30 | 2021-06-30 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 疾患を処置するためのgls1阻害薬 |
WO2017062354A1 (en) | 2015-10-05 | 2017-04-13 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
BR112018012660B1 (pt) | 2015-12-22 | 2023-12-19 | Board Of Regents, The University Of Texas System | Sal, solvato, ou polimorfo de um composto; polimorfo de composto sólido; composição; e uso de um sal, solvato ou polimorfo |
KR20190040302A (ko) | 2016-08-25 | 2019-04-17 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 글루타미나제 억제제와의 병용 요법 |
US10195197B2 (en) | 2016-08-25 | 2019-02-05 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
CN107137401A (zh) * | 2017-03-28 | 2017-09-08 | 刘纪君 | 一种治疗产后抑郁症的药物组合物 |
WO2019079632A1 (en) | 2017-10-18 | 2019-04-25 | Board Of Regents, The University Of Texas System | GLUTAMINASE INHIBITOR THERAPY |
CN114805346A (zh) * | 2021-07-08 | 2022-07-29 | 成都硕德药业有限公司 | 杂环类衍生物、其制备方法及用途 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2037257A1 (en) * | 1970-07-28 | 1972-02-03 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn |
US4070400A (en) * | 1975-10-16 | 1978-01-24 | Merck & Co., Inc. | Diphenyl polyamides having a cyclohexylene moiety |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
CA2155759A1 (en) | 1993-03-29 | 1994-10-13 | Bernd Janssen | 1-amino-3-phenoxy propane derivatives as modulators of multi-drug resistance |
US5895748A (en) | 1996-11-27 | 1999-04-20 | Johnson; Keith R. | Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies |
DE69923681T2 (de) | 1998-06-18 | 2006-01-12 | Bristol-Myers Squibb Co. | Kohlenstoff substituierte aminothiazole als inhibitoren von cyclin-abhängigen kinasen |
US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
WO2001062206A2 (en) | 2000-02-22 | 2001-08-30 | Mount Sinai School Of Medicine Of New York University | N-cadherin modulated migration, invasion, and metastasis |
US6974667B2 (en) | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
US6451828B1 (en) * | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
DK1388734T3 (da) | 2002-08-01 | 2004-05-03 | Mtm Lab Ag | Metode til opløsningsbaseret diagnose |
WO2006040569A1 (en) | 2004-10-14 | 2006-04-20 | Astex Therapeutics Limited | Thiophene amide compounds for use in the treatment or prophylaxis of cancers |
US20080182865A1 (en) | 2005-03-11 | 2008-07-31 | Witta Samir E | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
WO2006101925A2 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
WO2008048967A1 (en) | 2006-10-16 | 2008-04-24 | University Of Rochester | Tripodal cyclohexane derivatives and their use as carbohydrate receptors |
US8563695B2 (en) | 2007-11-19 | 2013-10-22 | Genentech, Inc. | Antibodies that bind β2 |
US7951549B2 (en) | 2008-03-07 | 2011-05-31 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP3021120A1 (en) | 2009-02-20 | 2016-05-18 | Michael P. Lisanti | Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample |
US10532034B2 (en) | 2009-03-25 | 2020-01-14 | Cornell University | Inhibition of glutaminase C |
EP2419177A1 (en) | 2009-04-17 | 2012-02-22 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
US20130109643A1 (en) * | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
ES2638522T3 (es) | 2010-06-23 | 2017-10-23 | University Of Louisville Research Foundation, Inc. | Procedimientos para detectar cáncer |
WO2012006506A1 (en) | 2010-07-09 | 2012-01-12 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
WO2013043125A1 (en) * | 2011-09-20 | 2013-03-28 | Temasek Life Sciences Laboratory Limited | Enterovirus 71 specific antibodies and uses thereof |
JP6031527B2 (ja) * | 2011-11-21 | 2016-11-24 | キャリセラ バイオサイエンシーズ, インコーポレイテッド | グルタミナーゼのヘテロ環式阻害剤 |
US20150037354A1 (en) | 2012-03-15 | 2015-02-05 | The Resesrch Foundation for The State University of New York | Combination therapies including inhibitors of the extracellular domain of e-cadherin |
ES2761951T3 (es) | 2012-11-21 | 2020-05-21 | Agios Pharmaceuticals Inc | Inhibidores de glutaminasa y métodos de uso |
US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
US20160008380A1 (en) | 2013-03-06 | 2016-01-14 | The Johns Hopkins University | Targeting glutamine metabolism in brain tumors |
CA2934700A1 (en) | 2014-01-06 | 2015-07-09 | Rhizen Pharmaceuticals Sa | Glutaminase inhibitors |
AU2015231053B2 (en) | 2014-03-21 | 2019-04-11 | Les Laboratoires Servier | Compounds and their methods of use |
-
2013
- 2013-11-21 ES ES13808311T patent/ES2761951T3/es active Active
- 2013-11-21 SG SG11201504022RA patent/SG11201504022RA/en unknown
- 2013-11-21 BR BR112015011756A patent/BR112015011756A2/pt not_active Application Discontinuation
- 2013-11-21 JP JP2015544128A patent/JP6333280B2/ja not_active Expired - Fee Related
- 2013-11-21 MX MX2015006478A patent/MX369691B/es active IP Right Grant
- 2013-11-21 US US14/646,239 patent/US10011574B2/en active Active
- 2013-11-21 KR KR1020157016411A patent/KR20150085078A/ko not_active Application Discontinuation
- 2013-11-21 CN CN201380070378.2A patent/CN105263915B/zh not_active Expired - Fee Related
- 2013-11-21 CA CA2892089A patent/CA2892089A1/en not_active Abandoned
- 2013-11-21 EA EA201590997A patent/EA029531B1/ru not_active IP Right Cessation
- 2013-11-21 WO PCT/US2013/071212 patent/WO2014081925A1/en active Application Filing
- 2013-11-21 AU AU2013347933A patent/AU2013347933C1/en not_active Ceased
- 2013-11-21 US US14/085,947 patent/US9303002B2/en active Active
- 2013-11-21 EP EP13808311.8A patent/EP2922832B1/en active Active
-
2015
- 2015-05-21 IL IL238959A patent/IL238959A/en active IP Right Grant
-
2016
- 2016-02-18 HK HK16101849.3A patent/HK1213889A1/zh unknown
-
2018
- 2018-06-04 US US15/996,723 patent/US10414740B2/en not_active Expired - Fee Related
- 2018-06-28 AU AU2018204692A patent/AU2018204692A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1213889A1 (zh) | 2016-07-15 |
CN105263915B (zh) | 2019-04-12 |
IL238959A (en) | 2017-12-31 |
WO2014081925A1 (en) | 2014-05-30 |
EA029531B1 (ru) | 2018-04-30 |
AU2013347933A2 (en) | 2015-07-09 |
EP2922832B1 (en) | 2019-10-09 |
CA2892089A1 (en) | 2014-05-30 |
AU2013347933C1 (en) | 2018-10-04 |
JP6333280B2 (ja) | 2018-05-30 |
KR20150085078A (ko) | 2015-07-22 |
MX369691B (es) | 2019-11-19 |
AU2018204692A1 (en) | 2018-07-19 |
EA201590997A1 (ru) | 2015-11-30 |
AU2013347933A1 (en) | 2015-06-11 |
US20140142146A1 (en) | 2014-05-22 |
JP2016500107A (ja) | 2016-01-07 |
IL238959A0 (en) | 2015-07-30 |
EP2922832A1 (en) | 2015-09-30 |
US10414740B2 (en) | 2019-09-17 |
US10011574B2 (en) | 2018-07-03 |
US20180370930A1 (en) | 2018-12-27 |
ES2761951T3 (es) | 2020-05-21 |
US20150299152A1 (en) | 2015-10-22 |
CN105263915A (zh) | 2016-01-20 |
US9303002B2 (en) | 2016-04-05 |
MX2015006478A (es) | 2015-12-03 |
SG11201504022RA (en) | 2015-06-29 |
AU2013347933B2 (en) | 2018-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
BR112015011830A2 (pt) | compostos e seus métodos de utilização | |
MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
CL2015002151A1 (es) | Biaril amide compuestos como inhibidores de quinasa | |
EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
CR20150462A (es) | Inhibidores de erk y sus usos | |
MX2016007801A (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
BR112016006319A2 (pt) | inibidores de irak e usos dos mesmos | |
MX356368B (es) | Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
EA202092456A2 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
EA201591137A1 (ru) | Ингибиторы mk2 и их применения | |
BR112015001838A2 (pt) | composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo. | |
EA201400178A1 (ru) | Лечение рака молочной железы | |
CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
UY34636A (es) | Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso | |
CL2015003595A1 (es) | Inhibidores/antiandrógenos novedosos de cyp17 | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
CR20140367A (es) | Inhibidores de iap | |
BR112017009265A2 (pt) | apilimode para uso no tratamento do câncer colorretal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B25G | Requested change of headquarter approved |
Owner name: AGIOS PHARMACEUTICALS, INC. (US) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |